Literature DB >> 12216090

Role of 5-aminolevulinic acid in the detection of urothelial premalignant lesions.

Dirk Zaak1, Edwin Hungerhuber, Peter Schneede, Herbert Stepp, Dominic Frimberger, Stefan Corvin, Nikolaus Schmeller, Martin Kriegmair, Alfons Hofstetter, Ruth Knuechel, Ruth Knöchel.   

Abstract

BACKGROUND: The authors evaluated the role of 5-aminolevulinic acid (5-ALA)-induced fluorescence endoscopy (AFE) in the detection of flat urothelial lesions in light of the suggestions made for flat neoplastic lesions within the 1999 World Health Organization (WHO) classification of urinary bladder tumors.
METHODS: From 1995 to 2000, 713 patients underwent 1414 AFE procedures for the detection of transitional cell carcinoma of the bladder (TCCB). Fluorescence imaging was performed with an incoherent light source (D-light; 380-440 nm) that was filtered for efficient protoporphyrin IX excitation and with cystoscopes partially blocking reflected excitation light to enable fluorescence evaluation by a red/blue color contrast 2-3 hours after 50 mL of a 3% solution of 5-ALA was instilled into the bladder. In total, 3834 biopsy specimens (mean, 2.7 specimens per AFE procedure) were taken.
RESULTS: Malignant disease was found in 1250 (32.6%) of all biopsies, with 304 biopsies (24.3%) showing carcinoma in situ (cis) and dysplasia II degrees (dys II) according to the previous diagnostic criteria of the WHO. Under prior conventional white-light endoscopy, 30.3% of specimens with dys II and 52.8% of specimens with cis had been missed.
CONCLUSIONS: The current results suggest that 5-ALA may be more effective in the detection of flat urothelial lesions than the current diagnostic devices. Copyright 2002 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12216090     DOI: 10.1002/cncr.10821

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  24 in total

Review 1.  [Diagnostic procedure for bladder cancer. Standards and current developments].

Authors:  A Karl; S Tritschler; D Zaak; D Tilki; C Stief; M Burger
Journal:  Urologe A       Date:  2010-10       Impact factor: 0.639

Review 2.  [Standards and perspectives in diagnosis and therapy of bladder carcinoma].

Authors:  C Stief; D Zaak; M Stöckle; U Studer; R Knuechel; C Rödel; R Sauer; H Rubben
Journal:  Urologe A       Date:  2006-09       Impact factor: 0.639

Review 3.  Chemoprevention of bladder cancer.

Authors:  Dragan J Golijanin; David Kakiashvili; Ralph R Madeb; Edward M Messing; Seth P Lerner
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

4.  Early detection of urothelial premalignant lesions using hexaminolevulinate fluorescence cystoscopy in high risk patients.

Authors:  Salvatore Blanco; Marco Raber; Biagio Eugenio Leone; Luca Nespoli; Marco Grasso
Journal:  J Transl Med       Date:  2010-11-22       Impact factor: 5.531

Review 5.  Fluorescence Imaging for Cancer Screening and Surveillance.

Authors:  K E Tipirneni; E L Rosenthal; L S Moore; A D Haskins; N Udayakumar; A H Jani; W R Carroll; A B Morlandt; M Bogyo; J Rao; Jason M Warram
Journal:  Mol Imaging Biol       Date:  2017-10       Impact factor: 3.488

Review 6.  [Fluorescence cystoscopy. Perspective in clinical practice and research].

Authors:  P Jichlinski; B Lovisa; C Erling; D Aymon; H van den Berg; G Wagnieres
Journal:  Urologe A       Date:  2008-08       Impact factor: 0.639

7.  Fractionated intravesical radioimmunotherapy with (213)Bi-anti-EGFR-MAb is effective without toxic side-effects in a nude mouse model of advanced human bladder carcinoma.

Authors:  Julia Fazel; Silvia Rötzer; Christof Seidl; Benedikt Feuerecker; Michael Autenrieth; Gregor Weirich; Frank Bruchertseifer; Alfred Morgenstern; Reingard Senekowitsch-Schmidtke
Journal:  Cancer Biol Ther       Date:  2015-07-15       Impact factor: 4.742

8.  Measurement conditions for flow cytometry analyses of cell lines from urological carcinomas.

Authors:  Angelika Tölle; Ziyad Abdallah; Klaus Jung; Hans Bäumler
Journal:  J Fluoresc       Date:  2010-02-26       Impact factor: 2.217

9.  [Diagnosis of urothelial carcinoma].

Authors:  A Karl; D Zaak; D Tilki; E Hungerhuber; M Staehler; S Denzinger; P Stanislaus; S Tritschler; F Strittmatter; C Stief; M Burger
Journal:  Urologe A       Date:  2008-03       Impact factor: 0.639

Review 10.  [Fluorescence cystoscopy at bladder cancer: present trials].

Authors:  D Zaak; A Karl; H Stepp; S Tritschler; D Tilki; M Burger; R Knuechel; C Stief
Journal:  Urologe A       Date:  2007-11       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.